Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhen-Yu He

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.
Pageof 19